Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as 68Ga-R10602 injection
68Ga-R10602 · 1 trial · 3 indications
Number of participants with adverse events as assessed by NCI-CTCAE v5.0, including grade
Number of participants with serious adverse events
Number of participants with clinically significant change in clinical laboratory parameters
| Arm | Type | Description |
|---|---|---|
| 68Ga-R10602 Imaging Optimization Portion (Cohort 1) | OTHER | 68Ga-R10602 injection at pre-defined dose levels. PET/CT imaging at pre-defined timepoints. |
| 68Ga-R10602 Imaging Confirmation Portion (Cohort 2) | OTHER | 68Ga-R10602 injection at the selected dose level. PET/CT imaging at a single timepoint. |
| Name | Type | Description |
|---|---|---|
| 68Ga-R10602 injection | DRUG | 68Ga-R10602 is a gallium-labeled small molecule radioligand that is designed to localize tumor lesions in hormone receptor positive breast cancer |
Inclusion Criteria: 1. Breast Cancer Eligibility: * Population 1: Pathologically confirmed ER and/or PR positive, locoregionally recurrent or metastatic breast cancer that is refractory to endocrine therapy (progression on at least one line of endocrine therapy and determined by the investigato...
68Ga-R10602 is an investigational small molecule imaging agent being developed by Crinetics Pharmaceuticals, Inc. It is designed for use in locoregionally recurrent hormone-receptor positive breast cancer. It is a Phase 1 clinical-stage asset and has been studied in a single completed trial.
68Ga-R10602 is being studied for locoregionally recurrent hormone-receptor positive breast cancer. The completed Phase 1 trial also enrolled patients with metastatic hormone receptor positive breast cancer and hormone receptor positive breast adenocarcinoma. It is an investigational agent and is not approved for commercial use.
68Ga-R10602 is being developed by Crinetics Pharmaceuticals, Inc., which trades on the Nasdaq under the ticker CRNX. The company is the sponsor of the clinical program for this imaging agent in hormone-receptor positive breast cancer.
68Ga-R10602 is in Phase 1 development. The program has one completed Phase 1 trial and no active trials. It is an investigational agent and has not been approved by the FDA for any indication.
68Ga-R10602 has been evaluated in one clinical trial, NCT06745804, titled Study of 68Ga-R10602. That Phase 1 trial is completed and enrolled 27 participants across sites in the United States. It was a controlled study in adults aged 18 years and older, and it was not randomized or double blinded.
Yes. 68Ga-R10602 injection is another name for 68Ga-R10602, the investigational imaging agent developed by Crinetics Pharmaceuticals, Inc. Both names refer to the same Phase 1 asset being studied in hormone-receptor positive breast cancer.